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Background: COPD is a significant cause of morbidity and mortality in the Veterans Health Administration (VHA).
To determine the clinical factors associated with the cost of COPD management, we analyzed the relationship
between clinical characteristics and COPD healthcare costs at the Cincinnati VAMC.
Methods: We queried the VHA Decision Support System for patients diagnosed with COPD at the Cincinnati VAMC
and calculated their VHA COPD-related encounters and costs in FY2008. Patients were ranked by COPD-related cost.
We determined the detailed clinical characteristics of patients selected by modified systematic sampling and
performed univariate and multivariable ordinary linear regression analysis to determine factors associated with cost.
Results: 3263 Veterans had 11,869 encounters with a primary or secondary diagnosis of COPD: 10,032 clinic visits,
505 emergency department (ED) visits, and 1,332 hospitalizations and incurred a total COPD-related healthcare cost
of $21.4 M: $2.4 M clinic visits, $0.21 M ED visits, and $18.7 M hospitalizations and $0.89 M for COPD-related
prescription costs. When the patients were ranked by VHA healthcare costs, the top 20% of patients accounted for
86% of the total costs and 57% of the total encounters with a primary or secondary diagnosis code of COPD and
90% of the total costs and 75% of the total encounters with a primary diagnosis code of COPD. The clinical
characteristics and VHA healthcare costs of 840 of the 3263 unique individuals with COPD were analyzed to
determine those characteristics associated with increased COPD-related costs. Univariate analysis showed significant
associations with 24 clinical variables; the 4 most highly associated factors were nursing home residence, total
hospital admissions, use of oral corticosteroids, and supplemental oxygen (p < 0.001 for all). In multivariate analysis,
total number of admissions (p < 0.001), management by a pulmonologist (p < 0.001), number of clinic visits
(p < 0.001), use of short acting anticholinergic (p = 0.001), forced expiratory volume in 1 second (FEV1) (p = 0.011),
number of prescriptions (p = 0.011), body mass index (BMI) (p = 0.025), and use of inhaled corticosteroid (p = 0.043)
were associated with COPD management cost.
Conclusion: The total number of admissions, clinic visits, physiologic impairment, BMI, number of medications, and
type of provider are strongly associated with the total cost of COPD management. These factors may be used to
focus COPD management toward patients with the potential for high utilization of healthcare resources.
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Chronic obstructive pulmonary disease (COPD) is a
progressive, debilitating lung disorder characterized by
non-normalizing airflow limitation. At the Cincinnati
Veteran’s Administration Medical Center (VAMC),
the prevalence of airflow limitation is estimated to be
33-43% and COPD is significantly under-diagnosed
and misdiagnosed [1]. In a 1996–2001 utilization review,
19% of men and 17% of women who received care from the
Veterans Healthcare Administration (VHA) were diagnosed
with COPD and COPD was the fourth most common
discharge diagnosis at VHA hospitals [2]. Further, COPD
care is a major expense; the VHA spent an estimated
$5.5 billion to care for approximately 969,000 Veterans with
COPD in 2004 [3]. COPD is a common disorder of
Veterans that causes significant morbidity and mortality
and its treatment is a major expense within the VHA.
The clinical course of COPD is marked by acute
exacerbations (AECOPD) that often precipitate healthcare
encounters. After an AECOPD, patients frequently do not
recover to the prior level of lung function, and have a
lower quality of life and reduced survival compared
with individuals who do not have AECOPD’s [4-6].
AECOPD’s account for approximately 40% of all direct
Medicare expenses for the treatment of COPD [5,7] and
the number of hospitalizations is a primary contributor to
COPD-related healthcare costs [8,9]. Numerous clinical
variables have been associated with hospital admissions
for AECOPD [7,10-25]. Reduced pulmonary function,
prior hospitalizations for AECOPD, and use of systemic
steroids are the most frequently identified predictors of
hospitalization for AECOPD.
The distribution of healthcare costs among Veterans with
COPD and the clinical characteristics that are associated
with greater costs have not been well studied within the
VHA [26,27]. The goal of this study was to determine the
clinical characteristics of Veterans with COPD that associ-
ate with COPD-related and total VHA healthcare costs and
their utilization of VHA resources for COPD management.
Methods
Study design and patient population
We queried the VHA Decision Support System (DSS) for
the names of all Veterans with a primary or secondary
diagnosis of COPD (496.xx), chronic bronchitis (491.xx),
and emphysema (492.xx) who received care at the
Cincinnati VAMC in the fiscal year 2008 (October 1,
2007 to September 31, 2008) and calculated their individual
VHA total and COPD-related healthcare encounters
and costs. Healthcare encounters were defined by
DSS variables: outpatient visits, ED visits not associated
with hospitalization, and hospitalizations. We defined
encounters and cost for which the primary or secondary
diagnosis was COPD (496.xx), chronic bronchitis (491.xx),or emphysema (492.xx) as COPD-related. These patients
were ranked by COPD-related health costs and grouped
by quintiles.
After reviewing the literature, we identified clinical
factors associated with healthcare costs related to COPD
(Additional file 1). Patients were selected by a modified
stratified systematic sampling: every other patient in the
quintile with the greatest COPD-related healthcare costs
and every fourth patient in the remaining quintiles. If a
patient received primary or pulmonary care from non-VA
providers, airflow limitation (FEV1/FVC< 0.7) was not
present on spirometry, or if they were in hospice care, they
were excluded and replaced by the next patient on the rank
list (Figure 1). We reviewed each patient’s complete
VHA electronic medical record including progress
notes (inpatient, outpatient and nursing home), discharge
summaries, medication lists, pulmonary function tests,
echocardiographic data, and phone notes for demographic
data and 16 risk factors for COPD exacerbations.
This study was approved by the University of Cincinnati
Institutional Review Board and the Cincinnati VAMC
Research and Development Committee.
Statistical analysis
All quantitative variables are described using appropriate
summary statistics (mean, median, standard deviation
(SD), interquartile range (IQR) and range); categorical
variables are presented using frequency and proportions.
COPD-related cost and total health care cost were the
primary outcomes. Initial healthcare encounter and cost
analysis were performed using the DSS data from the
entire population and the remaining analysis used the
sampled subpopulation. Both primary outcomes were
log transformed to normalize their distributions. Univariate
associations of cofactors with log transformed health care
costs were assessed using ordinary linear regression.
Multicollinearity was determined by calculating variance
inflation factors (VIF). Variables with VIF greater than 10
were considered to be multicollinear factors. However, no
variable was identified as a multicollinear variable. Stepwise
multiple linear regression was used to identify the adjusted
association of cofactors with the outcomes. The cofactors
identified in the univariate regression analyses at 10% level
of significance were included in the stepwise multivariable
linear regression analysis. The inclusion and exclusion
criteria were set at 5% and 10%, respectively, in the stepwise
regression. The multiple linear regression results are shown
using adjusted regression coefficients and their 95%
confidence intervals (CI) and p-values. The multiple linear
regression analyses were again developed after excluding
the probable outliers. However, there was no change
observed in the results with or without outliers. Thus, the
final multiple linear regression analysis was conducted on
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Figure 1 Patient selection diagram. Patients were selected by a modified stratified systematic sampling: every other patient in the first quintile
with the greatest COPD-related healthcare costs and every fourth patient in the remaining quintiles. If a patient received primary or pulmonary
care from non-VA providers, airflow limitation (FEV1/FVC < 0.7) was not present on spirometry, or if they were in hospice care, they were excluded
and replaced by the next patient on the rank list.
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variables that had more missing observations. P-values less
than 5% level of significance were considered significant.
All analyses were performed using SAS 9.2 (SAS Institute
Inc., Cary, NC, USA.).
Results
Healthcare encounters and cost analysis
3263 unique individuals with age 67 ± 11 years (mean ± SD)
were diagnosed with and received care for COPD at the
Cincinnati VAMC in FY08. These individuals had 11,869
encounters with a primary or secondary diagnosis of
COPD: 10,032 clinic visits (3.07 ± 0.08 visits/person),
505 emergency department (ED) visits (0.15 ± 0.01
visits/person), and 1,332 hospitalizations (0.410 ± 02
hospitalizations/person) and incurred a total COPD-related
healthcare cost of $21.4 M: $2.4 M clinic visits, $0.21 ED
visits, and $18.7 M hospitalizations and $0.89 M for
COPD-related prescription costs. Veterans with COPD had
3.64 ± 0.09 total COPD-related encounters per person with
a mean cost of $6546 ± 302/person. The median total
COPD-related healthcare cost per person was $1004(417, 4041) (median (25th and 75th percentiles)).
2877 Veterans (88.2%) had at least one clinic visit
whereas only 876 (26.8%) had an admission with a
primary or secondary diagnosis of COPD. Of those
Veterans who had at least one clinic visit for COPD,
the average number of visits was 3.49 ± 0.09 visits/person
and the median was 2 visits/person (range 1–56). For
those patients with at least one admission, the mean
number of admissions was 1.5 ± 0.2 admissions/person
and the median was 1 admission/person (range 1–11).
The distributions of costs and encounters for a primary
diagnosis of COPD and for primary and secondary
diagnosis of COPD are shown in Figures 2 and 3.
When the patients were ranked by VHA healthcare
costs, the top 20% of patients accounted for 86% of
the total costs and 57% of the total encounters with
a primary or secondary diagnosis code of COPD and
90% of the total costs and 75% of the total encoun-
ters with a primary diagnosis code of COPD. All
hospitalizations and ED visits and 69% of outpatient
encounters with a primary diagnosis of COPD occurred in
this top quintile.
Encounters or Cost (fraction of total) For Primary Diagnosis of COPD
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Figure 2 Encounters and costs for a primary diagnosis of COPD
at the cincinnati VAMC in FY08. Costs are represented by the
green line and encounters (outpatient visits, emergency department
visits, and hospitalizations) by the red line. FY: fiscal year; COPD:
chronic obstructive pulmonary disease.
Table 1 Summary of categorical demographic and clinical
characteristics


















Coronary Artery Disease 240 (29%)
Depression 204 (24%)
Diabetes Mellitus 181 (22%)






Long acting beta agonist 271 (32%)
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The demographics and clinical characteristics of the
study population are presented in Tables 1, 2, and 3.
COPD-related healthcare costs
The median total COPD cost according to various
clinical factors is shown in Figure 4. Factors associated
with COPD-related healthcare costs by univariate
analysis are shown in Table 4. For every increase in the
average number of admissions by one, the total average
COPD cost increased by 120%; for every increase in the
average number of ED visits by one, the total average
COPD cost increased by 70%. Multivariable regression
analysis demonstrated that 8 factors were significantlyEncounters or Cost (fraction of total) For Primary and Secondary Diagnosis of COPD
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Cost
Encounters
Figure 3 Encounters and costs for primary and secondary
diagnosis of COPD at the cincinnati VAMC in FY08. Costs are
represented by the green line and encounters (outpatient visits,
emergency department visits, and hospitalizations) by the red line.
FY: fiscal year; COPD: chronic obstructive pulmonary disease.
Short acting anti-muscarinic 473 (56%)
Long acting anti-muscarinic 124 (15%)
Inhaled corticosteroid 226 (40%)
Oral corticosteroid 39 (5%)
Supplemental oxygen 196 (23%)
Theophylline 38 (4%)
Statin 467 (56)
Illicit drug use (303) 91 (17%)
Nursing home resident 36 (4%)
Treated by a pulmonologist 216 (26%)
COPD for > 5 years 260 (31%)
(Percentage is the proportion of patients with identified clinical characteristics)
COPD-chronic obstructive pulmonary disease.associated with total COPD-related cost (Table 5). For
every increase in the average number of admissions
by one, the total average COPD cost increased by
99% after adjusting for the effect of other significant
Table 2 Summary of quantitative demographic and
clinical characteristics
Variable N Mean ± SD Median (25th-75th
percentile)α
Age (years) 840 67.29 ±10.85 66 (59–79)
Hospitalizations* 840 0.49 ± 1.00 0 (0–1)
Clinic Visits* 840 4.16 ± 5.43 2 (1–5)
ED Visits* 840 0.28 ± 0.79 0 (0–8)β
Number of Prescriptions* 700 10.55 ± 9.49 7 (4–15)
BMI (kg/m2) 834 27.87 ± 6.83 27 (23–32)
FEV1 (L) 689 1.85 ± 0.80 1.76 (1.21-2.37)
FVC (L) 689 3.23 ± 0.98 3.12 (2.56-3.82)
DLCO (ml/min/mmHg) 540 14.34 ± 6.05 13.5 (9.9-18.2)
EF (%) 390 54 ± 12 58 (53–63)
Maximum serum
bicarbonate (mEq/L) 758 30.07 ± 3.68 30 (28–32)
Smoking (pack years) 259 62.77 ± 37.53 55 (36–80)
*Per patient; αexcept where indicated; β(minimum-maximum) SD, Standard
deviation; ED, Emergency department; BMI, Body mass index; FEV1, Forced
expiratory volume in 1 second; FVC, Forced vital capacity; DLCO, Diffusing
capacity; EF, Ejection fraction.
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cing the total number of COPD admissions from the
50th percentile (2 hospitalizations/year) to the 25th
percentile (1 hospitalization/year) would reduce the
total COPD related healthcare cost by 6% relative to
its average cost.
Total healthcare costs
Univariate analysis revealed 22 variables that were
significantly associated with total healthcare costs (Table 4).Table 3 Comorbidities and Spirometry per Quintile
1st Quintile 2nd Quintile
Comorbidity
Depression 38 (12%) 47 (37%)
Diabetes 31 (10%) 30 (24%)
Coronary artery
Disease 37 (12%) 58 (46%)
Hypertension 95 (30%) 108 (85%)
Heart failure 9 (3%) 8 (6%)
COPD >5 years 81 (25%) 58 (46%)
Spirometry
FEV1 (L) 1.56 ± 0.70 1.93 ± 0.88
FEV1% predicted 50.0 ± 20.2% 60.2 ± 22.7%
FVC (L) 3.04 ± 0.94 3.34 ± 1.07
FVC% predicted 77.7 ± 22.4% 83.8 ± 23.0%
FEV1/FVC 50.9 ± 14.4% 56.9 ± 13.5%
Comorbidites are presented as n, percentage of the quintile; Spirometry is presenteMultivariable regression analysis revealed 8 variables that
were significantly related to total healthcare costs (Table 5).
Diffusing capacity (DLCO), smoking status, and ejection
fraction were excluded from these analyses because of the
amount of missing data.
Discussion
Our study cohort of 3263 patients represented 9.3% of
the approximately 35,000 Veterans receiving care at
the Cincinnati VAMC during FY 2008. This estimated
prevalence of diagnosed COPD compares well with
the 8.2% prevalence rate among Veterans in the
southeastern US (Veterans Integrated Service Network
16) calculated by Sharafkhaneh and colleagues [26]
and the 9.40% prevalence of diagnosed COPD within
the VHA nationally in 1999 estimated by Yu and coworkers
[27]. Previously, we demonstrated that the prevalence of
measured airflow limitation was significantly greater than
the prevalence of diagnosed COPD and that two thirds of
Veterans with airflow limitation did not have a diagnosis of
COPD [1]. Assuming that only one third of patients with
COPD are diagnosed, the prevalence of diagnosed Veterans
with COPD, 9.3%, is comparable to our previously
measured 43% prevalence of airflow limitation using a
threshold of FEV1/FVC < 0.7.
The mean cost of COPD related care was $6546 with
a median cost of $1004 (417, 4041) (25th and 75th
percentiles) per patient annually. The Confronting
COPD survey estimated the annual cost of COPD per
patient per year in the US as $5646 [28]. An analysis of
US Medicare beneficiaries in 2004 demonstrated that
the attributable cost of COPD averaged about $6300 and
that patients with COPD were more likely to use healthcare3rd Quintile 4th Quintile 5th Quintile
38 (31%) 40 (31%) 41 (32%)
34 (26%) 49 (38%) 36 (28%)
48 (37%) 53 (41%) 43 ( 33%)
99 (76%) 108 (83%) 116 (90%)
5 (4%) 15 (12%) 8 (6%)
33 (25%) 45 (35%) 43 (33%)
2.14 ± 0.76 1.98 ± 0.70 2.25 ± 0.78
64.3 ± 19.1% 61.8 ± 18.2% 67.0 ± 20.5%
3.43 ± 0.94 3.14 ± 0.91 3.58 ± 0.93
82.6 ± 19.5% 79.1 ± 17.4% 85.5 ± 18.1%
62.1 ± 12.2% 62.3 ± 12.3% 62.0 ± 11.9%
d as mean ± standard deviation.
$30,000   $40,000
Figure 4 Contribution of clinical variables to median COPD cost. + variable present; - variable not present CAD-coronary artery disease;
HTN-hypertension; COPD-chronic obstructive pulmonary disease; SAMA-short acting anti-muscarinic agonist; LAMA-long acting anti-muscarinic
agonist; LABA-long acting beta agonist; ICS-inhaled corticosteroid.
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$20,500 greater than a matched comparison cohort [29]. In
a study of Veterans in the southeastern US, Sharfakhaneh
and colleagues [26] calculated the average cost of COPD
management to be $4,437 per year whereas Yu and
coworkers [27] estimated the average annual cost per
patient with COPD within the VHA in 1999 to be $10,618.
Studies in other healthcare systems have estimated the cost
of care for patients with COPD to be $11,841/year among
US Medicare recipients, and $11,580 /year in the TexasMedicaid healthcare system. Patients with COPD consume
between 1.33 and 3.4 fold more healthcare resources
compared with similar patients who do not have
COPD [30]. Similarly, Maryland Medicaid recipients
utilized 1.33-fold more healthcare resources and had
1.8-fold more adjusted average inpatient claims than
controls [31].
Our study and these prior studies examined healthcare
utilization in patients with a diagnosis of COPD.
However, the vast majority of patients with COPD
Table 4 Univariate analysis of factors associated with copd-related and total healthcare costs
COPD-related cost Total healthcare cost
Variables Unadjusted regression p-value Unadjusted regression p11-value
Coefficient Coefficient
[95% confidence limits] [95% confidence limits]
Age 0.003 [−0.008, 0.013] 0.627 −0.009 [−0.017, -0.001] 0.02
Female 0.413 [−0.252, 1.077] 0.223 0.192 [−0.309, 0.692] 0.452
Married −0.288 [−0.789, 0.213] 0.259 −0.527 [−0.904, -0.151] 0.006
Divorced 0.154 [−0.359, 0.666] 0.556 −0.222 [−0.608, 0.163] 0.258
Separated 0.010 [−0.733, 0.753] 0.979 0.004 [−0.555, 0.564] 0.987
Widowed 0.276 [−0.303, 0.856] 0.350 −0.248 [−0.684, 0.188] 0.264
Black 0.002 [−0.337, 0.341] 0.991 0.233 [−0.017, 0.483] 0.068
Current Smoker 0.750 [0.156, 1.345] 0.014 0.568 [0.14, 0.996] 0.009
Ever Smoker 0.749 [0.152, 1.346] 0.014 0.645 [0.215, 1.074] 0.003
Hospitalizations 1.196 [1.120, 1.271] <.0001 0.747 [0.68, 0.813] <.0001
Clinic visits 0.110 [0.091, 0.129] <.0001 0.055 [0.04, 0.04] <.0001
ED visits 0.695 [0.562, 0.828] <.0001 0.356 [0.252, 0.459] <.0001
Number of Prescriptions 0.049 [0.037, 0.060] <.0001 0.021 [0.012, 0.03] <.0001
BMI −0.015 [−0.031, 0.001] 0.067 0.012 [0, 0.025] 0.048
FEV1 −0.493 [−0.639, -0.349] <.0001 −0.019 [−0.13, 0.091] 0.73
FVC −0.300 [−0.422, -0.178] <.0001 −0.066 [−0.156, 0.024] 0.15
DLCO −0.070 [−0.092, -0.049] <.0001 −0.026 [−0.010, -0.01] 0.002
EF −1.192 [−2.568, 0.184] 0.089 −0.545 [−1.462, 0.371] 0.243
Maximum serum bicarbonate 0.086 [0.054, 0.118] <.0001 0.047 [0.024, 0.069] <.0001
CAD 0.282 [0.038, 0.527] 0.024 0.27 [0.086, 0.453] 0.004
Depression −0.102 [−0.360, 0.157] 0.440 0.281 [0.088, 0.475] 0.004
DM 0.194 [−0.075, 0.463] 0.157 0.416 [0.215, 0.617] <.0001
Heart failure 0.422 [−0.069, 0.914] 0.092 0.541 [0.172, 0.91] 0.004
Hypertension −0.119 [−0.348, 0.110] 0.309 0.137 [−0.035, 0.309] 0.119
Influenza vaccine −0.083 [−0.335, 0.168] 0.516 0.037 [−0.153, 0.227] 0.704
Pneumococcal vaccine 0.147 [−0.172, 0.466] 0.365 0.058 [−0.182, 0.298] 0.633
Long acting beta agonists 0.776 [0.545, 1.007] <.0001 0.178 [0, 0.355] 0.05
Short acting anti-muscarinic 0.756 [0.539, 0.974] <.0001 0.131 [−0.037, 0.298] 0.126
Long acting anti-muscarinic 0.964 [0.658, 1.269] <.0001 0.394 [0.161, 0.627] 0.001
Inhaled corticosteroids 0.815 [0.596, 1.034] <.0001 0.196 [0.27, 0.365] 0.023
Oral corticosteroids 1.034 [0.513, 1.556] <.0001 0.618 [0.225, 1.011] 0.002
Supplemental oxygen 1.081 [0.829, 1.333] <.0001 0.551 [0.358, 0.745] <.0001
Theophylline 0.619 [0.088, 1.150] 0.022 0.107 [−0.293, 0.507] 0.599
Statin −0.128 [−0.350, 0.095] 0.262 0.133 [−0.034, 0.301] 0.118
Illicit drug use −0.014 [−0.407, 0.380] 0.946 0.005 [−0.267, 0.276] 0.972
Nursing home resident 2.363 [1.839, 2.887] <.0001 1.682 [1.286, 2.078] <.0001
Treated by a pulmonologist 0.639 [0.389, 0.889] <.0001 0.359 [0.17, 0.549] <.001
COPD for > 5 years 0.335 [0.097, 0.574] 0.006 0.042 [−0.139, 0.222] 0.651
ED, Emergency department; BMI, Body mass index; FEV1, Forced expiratory volume in 1 second; FVC, Forced vital capacity; DLCO, Diffusing capacity; EF, Ejection
fraction; CAD, Coronary artery disease; DM, Diabetes mellitis; COPD, Chronic obstructive pulmonary disease.
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Table 5 Multivariable analysis of factors associated with copd-related and total healthcare costs
COPD-related cost Total health care cost
Variables Adjusted regression p-value Adjusted regression p-value
coefficient coefficient
[95% confidence limits] [95% confidence limits]
Hospitalizations 0.988 [0.926, 1.050] <0.001 0.609 [0.543, 0.674] <0.001
Clinic visits 0.053 [0.040, 0.067] <0.001 0.027 [0.015, 0.039] <0.001
Treated by a pulmonologist 0.299 [0.133, 0.464] <0.001 0.208 [0.053, 0.363] 0.009
Number of medications 0.012 [0.003, 0.021] 0.011 NS
FEV1 −0.133 [−0.234, -0.031] 0.011 NS
Short acting anti-muscarinic 0.246 [0.100, 0.393] 0.001 NS
BMI −0.012 [−0.023, -0.001] 0.025 NS
Inhaled corticosteroid 0.168 [0.005, 0.331] 0.043 NS
DM NS 0.291 [0.134, 0.449] <0.001
Depression NS 0.195 [0.040, 0.351] 0.014
Age NS −0.008 [−0.014, -0.002] 0.012
Nursing home resident NS 0.506 [0.104, 0.909] 0.014
Maximum serum bicarbonate NS 0.021 [0.003, 0.039] 0.026
FEV1, Forced expiratory volume in 1 second; BMI, Body mass index; DM, Diabetes mellitus; NS, Not significant.
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study of healthcare utilization prior to the diagnosis
of COPD, undiagnosed patients required 1.5-1.6-fold
more hospitalizations, ED visits, and office visits than
control patients and the costs increased over the 36 months
preceding diagnosis, often increasing dramatically just prior
to the diagnosis of COPD [32]. Similarly, in an analysis of
6,846 patients in the Lovelace Healthplan, Albuquerque,
NM, Mapel and coworkers [33] showed that total costs
were higher by an average of $1182 per person in the two
years before COPD diagnosis and $2,489 in the year before
diagnosis. Outpatient and pharmacy costs increased in the
months just before the diagnosis of COPD was established
[33]. Thus, since approximately 2/3 of Veterans with
COPD are not diagnosed and the cost of care for
these individuals is significantly increased, our study
and others that only utilized patients with a diagnosis
of COPD severely underestimate the true cost of COPD
within the VHA.
Utilization of healthcare costs is not uniformly distributed
among individuals with COPD. We showed that the top
quintile of patients with COPD (653 of 3263 patients
with COPD) incur the vast majority of the costs and
all hospitalizations and ED visits associated with
COPD (Figure 2). Similarly, Simon-Tuval and colleagues
[30] showed that the top quartile of 398 patients with
COPD consumed 63% of all costs. This distribution of
healthcare expenditures is very similar to the general US
population where the top 5% of the population accounted
for 49% of all health care expenditures in 2002 [34].
Within the VHA in 1999, 35% of Veterans had 3 or moreof the most prevalent chronic conditions and accounted
for 73% of the total VHA healthcare budget [27].
Similar to other investigators, we found that hospitali-
zations were the greatest contributor to total COPD
costs and accounted for 87% of total COPD related costs
(Figure 4). Other studies have estimated that between 40
and 75% of the total cost of COPD management is due to
hospitalizations for exacerbations [8,35-37]. Differences in
cost accounting may explain some of these differences.
Many of our patients had multiple hospitalizations for
COPD exacerbations; one patient had 11 admissions in
12 months. Among Medicare beneficiaries in 15 states,
approximately 20.5% of all admissions for COPD were
followed by readmission within 30 days with a mean cost
of $7,100 for the index admission and $10,900 for
readmissions for which COPD was a primary or secondary
diagnosis [38]. Approximately 63% of the total costs associ-
ated with management of COPD exacerbations are due to
further treatment after failure of initial management [39].
Thus, reduction of readmissions for treatment failure after
hospitalization for a COPD exacerbation may profoundly
reduce COPD related healthcare costs.
Other factors associated with increased COPD-related
healthcare costs included FEV1 which was inversely
related to total COPD cost. Most COPD guidelines
classify COPD severity based upon FEV1. Several studies
have shown that COPD related healthcare costs increase
as the severity of disease worsens [8,40-42]. Hilleman
and colleagues showed that the cost of care rose as lung
function declines, $1,681 for stage I, $5,037 for stage II,
and $10,812 for stage III COPD [8]. We also showed that
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COPD related costs. Patients with pulmonary consultations
had worse lung function (FEV1, 49% v. 61%) and lower
DLCO (37% v. 47%) than patients not cared for by a
pulmonologist. Similarly, higher COPD related costs were
associated with the use of more medications, especially
short acting anti-muscarinics and inhaled corticosteroids.
(At the time of this study, long acting anti-muscarinics were
not on the Cincinnati VAMC formulary.)
In contrast with other studies, we did not find
associations between COPD cost and comorbid illnesses,
including coronary artery disease, heart failure, diabetes,
and depression [30]. Diabetes and depression were, how-
ever, associated with greater total healthcare costs. Possible
explanations for these differences include different study
populations; Simon-Tuval and associates [30] studied
predominantly enrollees of the Clalit Health Services, the
largest health maintenance organization in Israel whereas
our population was Veterans receiving healthcare through
the VHA. Their population was diagnosed with COPD
clinically and included a larger proportion of women.
Limitations
Due to differences in patient populations, study design,
and cost accounting, it is difficult to compare our results
with other studies. Our population, being within the
VHA, is predominately male, white, and had an extensive
smoking history. One other study examining costs among
Veterans with COPD [26] included patients with bronchi-
ectasis and allergic alveolitis (hypersensitivity pneumonitis).
Thus, differences in study population may account for
some of the differences in results. Our study was a single
center retrospective review and the findings will need
to be extended to a larger national population. We
only measured healthcare utilization within the VHA and
did not capture nonVHA healthcare costs. Consequently
our findings may underestimate the total COPD related
healthcare costs of this population.
Conclusions
When the patients were ranked by VHA healthcare
costs, the top 20% of patients accounted for 86% of the
total costs and 57% of the total encounters with a
primary or secondary diagnosis code of COPD and 90%
of the total costs and 75% of the total encounters with a
primary diagnosis code of COPD. This top quintile
generated all ED visits and hospitalizations and the
majority of office visits. The total number of admissions,
clinic visits, physiologic impairment, BMI, number of
medications, and type of provider were strongly associated
with the total cost of COPD management. These factors
may be used to improve COPD management for those
patients who have the greatest potential for the highest
utilization of healthcare resources.Additional file
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